【佳學基因檢測】細胞外囊泡在膠質母細胞瘤發(fā)病機制中的新作用

腫瘤基因檢測十大公司排序

閱讀腫瘤基因解碼協(xié)會如何提升基因檢測的正確性知悉《Metab Brain Dis》在.?2022 Sep 9.發(fā)表了一篇題目為《細胞外囊泡在膠質母細胞瘤發(fā)病機制中的新作用》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Maryam Khayamzadeh,?Vahid Niazi,?Bashdar Mahmud Hussen,?Mohammad Taheri,?Soudeh Ghafouri-Fard,?Mohammad Samadian?等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內容關鍵詞：

生物標志物,表達,細胞外囊泡,膠質母細胞瘤,小RNA

腫瘤靶向治療基因檢測臨床應用結果

雖然腦腫瘤并不十分常見，但由于缺乏適當的治療和發(fā)現較晚，它們會導致高死亡率。膠質母細胞瘤是賊常見的原發(fā)性腦腫瘤類型。這種惡性腫瘤具有高度侵襲性的行為。已發(fā)現不同類型轉錄物的表達譜、許多基因組基因座的甲基化狀態(tài)和染色體畸變會影響膠質母細胞瘤的病程以及反復和轉移的傾向。賊近的研究表明，膠質母細胞瘤細胞產生細胞外囊泡，其貨物可以影響鄰近細胞的行為。幾種 miRNA，例如 miR-301a、miR-221、miR-21、miR-16、miR-19b、miR-20、miR-26a、miR-92、miR-93、miR-29a、miR-222、miR-已顯示 221 和 miR-30a 被膠質母細胞瘤來源的細胞外囊泡轉移并增強這些細胞的惡性行為。膠質母細胞瘤衍生的細胞外囊泡的其他成分是 EGFRvIII mRNA/蛋白、Ndfip1、PTEN、MYC ssDNA 和 IDH1 mRNA。在當前的綜述中，我們討論了關于膠質母細胞瘤來源的細胞外囊泡的分子組成及其對這種惡性腫瘤的進展及其對治療方式的耐藥性的影響的現有數據。表達;細胞外囊泡；膠質母細胞瘤；小RNA。

腫瘤發(fā)生與反復轉移國際數據庫描述：

While brain tumors are not extremely frequent, they cause high mortality due to lack of appropriate treatment and late detection. Glioblastoma is the most frequent type of primary brain tumor. This malignant tumor has a highly aggressive behavior. Expression profile of different types of transcripts, methylation status of a number of genomic loci and chromosomal aberrations have been found to affect course of glioblastoma and propensity for recurrence and metastasis. Recent studies have shown that glioblastoma cells produce extracellular vesicles whose cargo can affect behavior of neighboring cells. Several miRNAs such as miR-301a, miR-221, miR-21, miR-16, miR-19b, miR-20, miR-26a, miR-92, miR-93, miR-29a, miR-222, miR-221 and miR-30a have been shown to be transferred by glioblastoma-derived extracellular vesicles and enhance the malignant behavior of these cells. Other components of glioblastoma-derived extracellular vesicles are EGFRvIII mRNA/protein, Ndfip1, PTEN, MYC ssDNA and IDH1 mRNA. In the current review, we discuss the available data about the molecular composition of glioblastoma-derived extracellular vesicles and their impact on the progression of this malignant tumor and its resistance to therapeutic modalities.Keywords:?Biomarker; Expression; Extracellular vesicle; Glioblastoma; miRNA.